Penserra Capital Management LLC lifted its stake in PerkinElmer, Inc. (NYSE:PKI) by 325.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,326 shares of the medical research company’s stock after buying an additional 1,014 shares during the period. Penserra Capital Management LLC’s holdings in PerkinElmer were worth $112,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Phocas Financial Corp. purchased a new position in PerkinElmer in the 2nd quarter worth approximately $2,620,000. Bartlett & Co. LLC lifted its position in PerkinElmer by 430.1% in the third quarter. Bartlett & Co. LLC now owns 493 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 400 shares during the last quarter. Amica Retiree Medical Trust purchased a new stake in shares of PerkinElmer during the second quarter valued at approximately $48,000. CSat Investment Advisory L.P. grew its holdings in shares of PerkinElmer by 74.1% in the second quarter. CSat Investment Advisory L.P. now owns 538 shares of the medical research company’s stock worth $51,000 after purchasing an additional 229 shares during the last quarter. Finally, Coastal Capital Group Inc. purchased a new position in shares of PerkinElmer in the second quarter worth $58,000. Hedge funds and other institutional investors own 95.93% of the company’s stock.
Shares of PerkinElmer stock opened at $92.15 on Tuesday. The company has a current ratio of 1.30, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70. The company’s fifty day simple moving average is $87.88 and its two-hundred day simple moving average is $88.06. The company has a market cap of $10.32 billion, a P/E ratio of 25.53, a PEG ratio of 1.69 and a beta of 1.30. PerkinElmer, Inc. has a 12-month low of $71.83 and a 12-month high of $103.00.
The business also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. The ex-dividend date of this dividend is Thursday, January 16th. PerkinElmer’s dividend payout ratio is currently 7.76%.
Several equities research analysts have weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of PerkinElmer in a research report on Thursday, October 31st. Raymond James restated an “average” rating and issued a $51.00 price objective on shares of PerkinElmer in a research report on Tuesday, November 5th. Stifel Nicolaus reaffirmed a “buy” rating on shares of PerkinElmer in a research note on Thursday, November 21st. UBS Group lowered their price objective on shares of PerkinElmer from $101.00 to $92.00 and set a “neutral” rating for the company in a research note on Friday, October 18th. Finally, Piper Jaffray Companies lowered shares of PerkinElmer from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $104.00 to $89.00 in a report on Thursday, October 31st. Ten analysts have rated the stock with a hold rating and five have issued a buy rating to the company. PerkinElmer presently has an average rating of “Hold” and a consensus target price of $76.61.
In related news, Director Pascale Witz sold 1,043 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $90.67, for a total value of $94,568.81. Following the completion of the transaction, the director now directly owns 2,446 shares of the company’s stock, valued at $221,778.82. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.80% of the stock is owned by corporate insiders.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Recommended Story: Municipal Bonds
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.